Creating value in the lives of the people we serve, now and into the future UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge UCB share price More in UCB Shares Consensus by Visible Alpha Financial & Extra Financial performance Equity Story Download Center Corporate Governance Shareholders Financial Guidance The figures of the guidance 2025 as mentioned below were calculated on the same basis as the actual figures for 2024 and based on current rules and regulations. 2025 Revenue € 6.5-6.7bnStrong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, despite impact of 340B and IRA across portfolio. CIMZIA® volume growth expected to be overcompensated by pricing pressure 2025 adj. EBITDA 30%Continued gross margin improvement, operating leverage improvement, continued growth of marketing and sales expenses driven by top-line growth and relatively stable R&D expenses and continued EVENITY® earnings contribution 2025 Core EPS € 6.80 - 7.40based on an average of 190 million shares outstanding Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.comDiyana Mishu, Investor Relations ManagerTel: +32 2 599 7446E-mail: Diyana.Mishu@ucb.com Book a virtual meeting Send us feedback UCB IR App ×
